Aliskiren Hemifumarate; Amlodipine Besylate Patent Expiration
Aliskiren Hemifumarate; Amlodipine Besylate is Used for treating high blood pressure. It was first introduced by Novartis Pharmaceuticals Corp
Aliskiren Hemifumarate; Amlodipine Besylate Patents
Given below is the list of patents protecting Aliskiren Hemifumarate; Amlodipine Besylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tekamlo | US8613949 | Galenical formulations of organic compounds | Dec 21, 2029 | Novartis |
| Tekamlo | US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul 21, 2018
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Aliskiren Hemifumarate; Amlodipine Besylate's patents.
Latest Legal Activities on Aliskiren Hemifumarate; Amlodipine Besylate's Patents
Given below is the list recent legal activities going on the following patents of Aliskiren Hemifumarate; Amlodipine Besylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 31 Jan, 2022 | US8613949 |
| Maintenance Fee Reminder Mailed Critical
| 16 Aug, 2021 | US8613949 |
| Patent Issue Date Used in PTA Calculation Critical
| 24 Dec, 2013 | US8613949 |
| Recordation of Patent Grant Mailed Critical
| 24 Dec, 2013 | US8613949 |
| Email Notification Critical
| 05 Dec, 2013 | US8613949 |
| Issue Notification Mailed Critical
| 04 Dec, 2013 | US8613949 |
| Application Is Considered Ready for Issue Critical
| 22 Nov, 2013 | US8613949 |
| Dispatch to FDC | 22 Nov, 2013 | US8613949 |
| Issue Fee Payment Received Critical
| 20 Nov, 2013 | US8613949 |
| Issue Fee Payment Verified Critical
| 20 Nov, 2013 | US8613949 |
Aliskiren Hemifumarate; Amlodipine Besylate's Family Patents
